American Chemical Society
Presentation – Aug 09, Washington DC
Power of Ten Conference
Presentation – June 09, Baltimore, MD
Wharton Health Care Conference
Presentation – Feb 09, Philadelphia, PA
June 27 - 30, 2011 - Dr. Kelleher-Andersson, the President and CSO of Neuronascent, is planning to attend the BIO meeting in Washington D.C. This BIO International meeting “is the largest global event for the biotechnology industry”. It also “offers key networking and partnering opportunities” for small biotech companies like Neuronascent.
Dec 14, 2010- Judith Kelleher-Andersson, Ph.D., the founder and CSO of Neuronascent was an invited speaker at CBI’s 4th Annual Alzheimer’s Disease Drug Discovery Summit on December 14th in Washington DC. Dr. Kelleher-Andersson presented work on Neuronascent’s preclinical lead AD candidate and the status of neurogenesis for neurodegenerative diseases in a talk entitled “Utilizing neurogenic therapeutics in an effort to reverse Alzheimer’s disease”.
Dec 10, 2010 - Neuronascent receives a Maryland Biotechnology Center Translational Research award for their application entitled “Preclinical Development of Novel Neurogenic Depression Candidate,” The grant of $199,204.88 will support studies to move Neuronascent’s lead depression candidate toward human testing and determine whether this neurogenic agent will also be effective in improving cognitive capacity in young Down syndrome individuals. The Brain Translational Center at Johns Hopkins University under the leadership of Dr. Barbara Slusher will collaborate specifically to scale-up the synthesis of this small molecule compound and to determine if there could be any potential toxicity issues in moving toward human clinical testing.
Dec 31, 2010 - Neuronascent receives a Therapeutic Drug Discovery Grant awarded to companies that are presently developing therapeutics for diseases with unmet need. All applicants were examined both by NIH for scientific value and then by the IRS prior to receipt of award. Monies will be spent for further development costs for Neuronascent’s Alzheimer’s and Parkinson’s disease therapeutic candidates.